Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

W. Nathaniel Brennen, Huong Nguyen, Susan L. Dalrymple, Stephanie Reppert-Gerber, Jeesun Kim, John T. Isaacs, Hans Hammers

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Accurate modeling of angiogenesis in vitro is essential for guiding the preclinical development of novel anti-angiogenic agents and treatment strategies. The formation of new blood vessels is a multifactorial and multi-stage process dependent upon paracrine factors produced by stromal cells in the local microenvironment. Mesenchymal stem cells (MSCs) are multipotent cells in adults that can be recruited to sites of inflammation and tissue damage where they aid in wound healing through regenerative, trophic, and immunomodulatory properties. Primary stromal cultures derived from human bone marrow, normal prostate, or prostate cancer tissue are highly enriched in MSCs and stromal progenitors. Using conditioned media from these primary cultures, a robust pro-angiogenic response was observed in a physiologically-relevant three-dimensional fibrin matrix assay. To evaluate the utility of this assay, the allosteric HDAC4 inhibitor tasquinimod and the anti-VEGF monoclonal antibody bevacizumab were used as model compounds with distinct mechanisms of action. While both agents had a profound inhibitory effect on endothelial sprouting, only bevacizumab induced significant regression of established vessels. Additionally, the pro-angiogenic properties of MSCs derived from prostate cancer patients provides further evidence that selective targeting of this population may be of therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)71298-71308
Number of pages11
JournalOncotarget
Volume7
Issue number44
DOIs
StatePublished - Jan 1 2016

Fingerprint

Stromal Cells
Fibrin
Mesenchymal Stromal Cells
Prostate
Prostatic Neoplasms
Conditioned Culture Medium
Wound Healing
Vascular Endothelial Growth Factor A
Blood Vessels
Bone Marrow
Monoclonal Antibodies
Inflammation
Therapeutics
Population
Bevacizumab

Keywords

  • Angiogenesis
  • Mesenchymal stem cells (MSC)
  • Prostate
  • Stroma
  • Stromal paracrine factors

ASJC Scopus subject areas

  • Oncology

Cite this

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. / Brennen, W. Nathaniel; Nguyen, Huong; Dalrymple, Susan L.; Reppert-Gerber, Stephanie; Kim, Jeesun; Isaacs, John T.; Hammers, Hans.

In: Oncotarget, Vol. 7, No. 44, 01.01.2016, p. 71298-71308.

Research output: Contribution to journalArticle

Brennen, W. Nathaniel ; Nguyen, Huong ; Dalrymple, Susan L. ; Reppert-Gerber, Stephanie ; Kim, Jeesun ; Isaacs, John T. ; Hammers, Hans. / Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. In: Oncotarget. 2016 ; Vol. 7, No. 44. pp. 71298-71308.
@article{f60fa3524fa146169f6ea0e351335a08,
title = "Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay",
abstract = "Accurate modeling of angiogenesis in vitro is essential for guiding the preclinical development of novel anti-angiogenic agents and treatment strategies. The formation of new blood vessels is a multifactorial and multi-stage process dependent upon paracrine factors produced by stromal cells in the local microenvironment. Mesenchymal stem cells (MSCs) are multipotent cells in adults that can be recruited to sites of inflammation and tissue damage where they aid in wound healing through regenerative, trophic, and immunomodulatory properties. Primary stromal cultures derived from human bone marrow, normal prostate, or prostate cancer tissue are highly enriched in MSCs and stromal progenitors. Using conditioned media from these primary cultures, a robust pro-angiogenic response was observed in a physiologically-relevant three-dimensional fibrin matrix assay. To evaluate the utility of this assay, the allosteric HDAC4 inhibitor tasquinimod and the anti-VEGF monoclonal antibody bevacizumab were used as model compounds with distinct mechanisms of action. While both agents had a profound inhibitory effect on endothelial sprouting, only bevacizumab induced significant regression of established vessels. Additionally, the pro-angiogenic properties of MSCs derived from prostate cancer patients provides further evidence that selective targeting of this population may be of therapeutic benefit.",
keywords = "Angiogenesis, Mesenchymal stem cells (MSC), Prostate, Stroma, Stromal paracrine factors",
author = "Brennen, {W. Nathaniel} and Huong Nguyen and Dalrymple, {Susan L.} and Stephanie Reppert-Gerber and Jeesun Kim and Isaacs, {John T.} and Hans Hammers",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11347",
language = "English (US)",
volume = "7",
pages = "71298--71308",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

TY - JOUR

T1 - Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

AU - Brennen, W. Nathaniel

AU - Nguyen, Huong

AU - Dalrymple, Susan L.

AU - Reppert-Gerber, Stephanie

AU - Kim, Jeesun

AU - Isaacs, John T.

AU - Hammers, Hans

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Accurate modeling of angiogenesis in vitro is essential for guiding the preclinical development of novel anti-angiogenic agents and treatment strategies. The formation of new blood vessels is a multifactorial and multi-stage process dependent upon paracrine factors produced by stromal cells in the local microenvironment. Mesenchymal stem cells (MSCs) are multipotent cells in adults that can be recruited to sites of inflammation and tissue damage where they aid in wound healing through regenerative, trophic, and immunomodulatory properties. Primary stromal cultures derived from human bone marrow, normal prostate, or prostate cancer tissue are highly enriched in MSCs and stromal progenitors. Using conditioned media from these primary cultures, a robust pro-angiogenic response was observed in a physiologically-relevant three-dimensional fibrin matrix assay. To evaluate the utility of this assay, the allosteric HDAC4 inhibitor tasquinimod and the anti-VEGF monoclonal antibody bevacizumab were used as model compounds with distinct mechanisms of action. While both agents had a profound inhibitory effect on endothelial sprouting, only bevacizumab induced significant regression of established vessels. Additionally, the pro-angiogenic properties of MSCs derived from prostate cancer patients provides further evidence that selective targeting of this population may be of therapeutic benefit.

AB - Accurate modeling of angiogenesis in vitro is essential for guiding the preclinical development of novel anti-angiogenic agents and treatment strategies. The formation of new blood vessels is a multifactorial and multi-stage process dependent upon paracrine factors produced by stromal cells in the local microenvironment. Mesenchymal stem cells (MSCs) are multipotent cells in adults that can be recruited to sites of inflammation and tissue damage where they aid in wound healing through regenerative, trophic, and immunomodulatory properties. Primary stromal cultures derived from human bone marrow, normal prostate, or prostate cancer tissue are highly enriched in MSCs and stromal progenitors. Using conditioned media from these primary cultures, a robust pro-angiogenic response was observed in a physiologically-relevant three-dimensional fibrin matrix assay. To evaluate the utility of this assay, the allosteric HDAC4 inhibitor tasquinimod and the anti-VEGF monoclonal antibody bevacizumab were used as model compounds with distinct mechanisms of action. While both agents had a profound inhibitory effect on endothelial sprouting, only bevacizumab induced significant regression of established vessels. Additionally, the pro-angiogenic properties of MSCs derived from prostate cancer patients provides further evidence that selective targeting of this population may be of therapeutic benefit.

KW - Angiogenesis

KW - Mesenchymal stem cells (MSC)

KW - Prostate

KW - Stroma

KW - Stromal paracrine factors

UR - http://www.scopus.com/inward/record.url?scp=84995388864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995388864&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11347

DO - 10.18632/oncotarget.11347

M3 - Article

C2 - 27542256

AN - SCOPUS:84995388864

VL - 7

SP - 71298

EP - 71308

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -